Follow

BioStock Studio: Scandion Oncology’s CEO comments on ongoing rights issue

07 December 2020 - 09:18

Scandion Oncology recently announced that the company is raising 236 MSEK through a fully guaranteed rights issue. The subscription period runs from November 26 through December 10. BioStock caught up with Scandion Oncology’s CEO Bo Rode Hansen via video link to learn more about how the company plans to make the best of the raised capital.

Watch the full interview with Scandion Oncology's CEO Bo Rode Hansen at biostock.se:

https://www.biostock.se/2020/12/biostock-studio-scandion-oncologys-ceo-comments-on-ongoing-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Provided by: Cision
Nasdaq First North GM (Sweden)
Scandion Oncology A/S
Scandion Oncology A/S is a biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. Its first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients. The company also has s...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More